Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 12:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 3,573 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukemia
Interventions
Nelarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

T Cell Repertoire Analysis of Immune Mediated Skin Diseases

NCT00368784
Conditions
Psoriasis, Mycosis Fungoides
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
426 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2020
U.S. locations
1
States / cities
Sacramento, California
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, cytarabine, allogeneic bone marrow transplantation
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
New York, New York
Conditions
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Interventions
SGN-40, rituximab, gemcitabine
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 6 more
Conditions
Obesity, Mild
Interventions
TENS Active Treatment, Sham Device
Device
Lead sponsor
Elira, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Scottsdale, Arizona • Santa Monica, California • Miami, Florida + 2 more
Conditions
Relapsed/Refractory Aggressive B-cell Lymphomas
Interventions
MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Conditions
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), Non-Hodgkins Lymphoma (NHL), Hodgkins Disease (HD), Chronic Lymphocytic Leukemia (CLL)
Interventions
CDX-301, CDX-301 and plerixafor
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Conditions
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more
Conditions
Solid Tumors, Lymphoma
Interventions
PU-H71
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Interventions
Rituximab, N-803
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Columbus, Ohio + 1 more
Conditions
Lymphoma, Non-Hodgkin
Interventions
Inotuzumab ozogamicin, Rituximab, rituximab + gemcitabine, rituximab +bendamustine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
82
States / cities
Burbank, California • Fresno, California • Los Angeles, California + 42 more
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Zanubrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Aurora, Colorado • Newark, Delaware • Fort Myers, Florida + 21 more
Terminated Not applicable Interventional Accepts healthy volunteers

LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma

NCT00161239
Conditions
T-Cell Lymphoma
Interventions
Doxil, Methotrexate, L-Asparaginase, Prednisone
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Diffuse Large B-cell Lymphoma
Interventions
CC-5013 (lenalidomide), dexamethasone
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Glendale, Arizona • Beverly Hills, California • Miami, Florida + 15 more
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse, Lymphoma, Follicular
Interventions
TAK-659, Venetoclax
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Evanston, Illinois + 5 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

NCT00081861
Conditions
Lymphoma
Interventions
Avastin, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting Not applicable Interventional

Cannabis Use Disorder Treatment Study

NCT04567394
Conditions
Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Interventions
Peer Network Counseling-txt
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 25 Years
Enrollment
1,077 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Fort Collins, Colorado • Knoxville, Tennessee
Conditions
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions
Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Tucson, Arizona • Encinitas, California • La Jolla, California + 15 more
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bleomycin sulfate, recombinant interferon alfa, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methotrexate, prednisone, vincristine sulfate, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2011
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Terminated Phase 1Phase 2 Interventional Results available

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

NCT02867618
Conditions
Hodgkin Disease, Lymphoma, Non-hodgkin
Interventions
Carfilzomib, TGR-1202
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Recruiting No phase listed Observational Accepts healthy volunteers

Pre-malignant States to Hematologic Malignancies in Firefighters

NCT06870760
Conditions
Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, Non Hodgkin Lymphoma, Leukemia, Multiple Myeloma, Plasma Cell Disorder
Interventions
Monoclonal Gammopathy, Complete Blood Count with differential (CBC w/ diff), Clonal hematopoiesis (CHIP)
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Completed Phase 1Phase 2 Interventional Results available

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

NCT02264613
Conditions
Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma
Interventions
ALRN-6924
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Denver, Colorado + 9 more
Terminated Phase 2 Interventional Results available

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

NCT01746173
Conditions
T-cell Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions
Zilovertamab vedotin
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Orange, California • Whittier, California • Washington D.C., District of Columbia + 16 more